Egui, AdrianaThomas, M CarmenFernández-Villegas, AnaPérez-Antón, ElenaGómez, InmaculadaCarrilero, BartoloméDel Pozo, ÁngelCeballos, MaialenAndrés-León, EduardoLópez-Ruz, Miguel ÁngelGainza, EusebioOquiñena, EnriqueSegovia, ManuelLópez, Manuel Carlos2023-01-252023-01-252019-09-23http://hdl.handle.net/10668/14331One of the current greatest challenges of Chagas disease is the establishment of biomarkers to assess the efficacy of drugs in a short period of time. In this context, the reactivity of sera from 66 adults with chronic indeterminate Chagas disease (IND) for a set of four Trypanosoma cruzi antigens (KMP11, PFR2, HSP70, and 3973d) was analyzed before and after benznidazole treatment. The results showed that the reactivity against these antigens decreased at 9, 24, and 48 months after treatment. Moreover, the 42.4% and 68.75% of IND patients met the established standard criteria of therapeutic efficacy (STEC) at 24 and 48 months posttreatment, respectively. Meeting the STEC implied that there was a continuous decrease in the reactivity of the patient sera against the four antigens after treatment and that there was a substantial decrease in the reactivity for at least two of the antigens. This important decrease in reactivity may be associated with a drastic reduction in the parasite load, but it is not necessarily associated with a parasitological cure. After treatment, a positive PCR result was only obtained in patients who did not meet the STEC. The percentage of granzyme B+/perforin+ CD8+ T cells was significantly higher in patients who met the STEC than in those who did not meet the STEC (35.2% versus 2.2%; P enChagas diseaseTrypanosoma cruziantibodiesbenznidazolebiomarkerscellular responsecytokinescytotoxic moleculesseroconversiontherapeutic responseAdultBiomarkersCD8-Positive T-LymphocytesChagas DiseaseCytokinesEnzyme-Linked Immunosorbent AssayFemaleGranzymesHumansMaleMiddle AgedNitroimidazolesPerforinPolymerase Chain ReactionTrypanocidal AgentsTrypanosoma cruziYoung Adultresearch article31358581open access10.1128/AAC.02436-181098-6596PMC6761566https://europepmc.org/articles/pmc6761566?pdf=renderhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761566/pdf